Research programme: AAV vector gene therapy - Cell Genesys
Latest Information Update: 12 Oct 2006
At a glance
- Originator Cell Genesys
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Brain cancer
Most Recent Events
- 12 Oct 2006 Discontinued - Preclinical for Brain cancer in USA (unspecified route)
- 17 Jun 2003 Preclinical trials in Brain cancer in USA (unspecified route)